Literature DB >> 26883133

Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer.

Lukas Kaesmann1, Stefan Janssen1,2, Steven E Schild3, Dirk Rades4.   

Abstract

The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2-4 points were compared to 5-8 points. For the Age-Comorbidity Score, 2-6 points were compared to 7-10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0-2 were compared to grades 3-5. For the Simplified Comorbidity Score, 0-5 points were compared to 6-11 and 12-17 points. Charlson Comorbidity Index (p = 0.022) and MRC Breathlessness Scale (p < 0.001) showed significant associations with survival, the Age-Comorbidity Score a trend (p = 0.06). For the Simplified Comorbidity Score, no significant correlation was found (p = 0.54). Absolute differences in survival ≥20 % were observed for the MRC Breathlessness Scale at 1, 2, and 3 years, for the Charlson Comorbidity Index at 1 year, and for the Age-Comorbidity Score at 2 years. Thus, particularly the MRC Breathlessness Scale can contribute to personalization of the treatment of SCLC.

Entities:  

Keywords:  Charlson Comorbidity Index; MRC Breathlessness Scale; Radiochemotherapy; Small cell lung cancer; Survival prognosis

Mesh：

Substances：

Year:  2016        PMID： 26883133     DOI： 10.1007/s00408-016-9857-4

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


  11 in total

1.  Timely airway stenting improves survival in patients with malignant central airway obstruction.

Authors:  Syed S Razi; Robert S Lebovics; Gary Schwartz; Manu Sancheti; Scott Belsley; Cliff P Connery; Faiz Y Bhora
Journal:  Ann Thorac Surg       Date:  2010-10       Impact factor: 4.330

2.  The MRC breathlessness scale.

Authors:  Chris Stenton
Journal:  Occup Med (Lond)       Date:  2008-05       Impact factor: 1.611

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  The effect of different comorbidities on survival of non-small cells lung cancer patients.

Authors:  Maria Iachina; Erik Jakobsen; Henrik Møller; Margreet Lüchtenborg; Anders Mellemgaard; Mark Krasnik; Anders Green
Journal:  Lung       Date:  2014-12-17       Impact factor: 2.584

5.  Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.

Authors:  Selim Firat; Roger W Byhardt; Elizabeth Gore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

6.  Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation.

Authors:  Tracey G Simon; Michael D Beland; Jason T Machan; Thomas Dipetrillo; Damian E Dupuy
Journal:  Eur J Radiol       Date:  2012-07-24       Impact factor: 3.528

7.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

8.  Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

Authors:  Abhilash Gazula; Elizabeth H Baldini; Aileen Chen; David Kozono
Journal:  Lung       Date:  2013-10-27       Impact factor: 2.584

9.  Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.

Authors:  Neil Kopek; Merete Paludan; Jørgen Petersen; Anders Traberg Hansen; Cai Grau; Morten Høyer
Journal:  Radiother Oncol       Date:  2009-06-24       Impact factor: 6.280

10.  A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.

Authors:  B Colinet; W Jacot; D Bertrand; S Lacombe; M-C Bozonnat; J-P Daurès; J-L Pujol
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640
View more
  2 in total

1.  Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer.

Authors:  Leon SchnÖller; Lukas KÄsmann; Julian Taugner; Reem Abdo; Chukwuka Eze; Farkhad Manapov
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder.

Authors:  Lisa Manig; Stefan Janssen; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.